The decisions made at the Greater Manchester Medicines Management Group (GMMMG) and Clinical Effectiveness and Governance Committee (CEG) at their meetings in February and March 2026 have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Updates to formulary
- Fenofibrate for diabetic retinopathy – green (specialist advice)
- Fluticasone / azelastine nasal spray – grey and green, prescribe generically
- Mometasone / olopatadine nasal spray – grey and green, alternative to fluticasone / azelastine
- Sacubitril / valsartan – green (specialist advice)
- Cabotegravir for HIV PrEP – red
Available at https://www.greatermanchesterformulary.nhs.uk/. Links to NICE guidance and MHRA safety advice added as appropriate. For full details of formulary and RAG updates, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Pathways and guidelines
The following are also available at https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/:
- Interim position statements for incretin therapies and GM implementation of updates to NICE NG28
- SGLT2 inhibitor pathway and position statement
- Lipid management primary prevention pathway
- Statin intolerance pathway
- Safety pen needles and lancets position statement
- Update to adult hypertension medication overview table
For full details of new and updated pathways, see the decision summaries available at https://gmmmg.nhs.uk/meetings/decision-summaries/.
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.